0625 GMT - Concerns about Roche's upcoming clinical trial results persist despite improvements in its midstage pipeline over the past year, Berenberg analysts say in a note. The Swiss drugmaker's higher implemented threshold in assessing drug candidates should begin to shift the mix of its late-stage readouts toward higher return-on-investment assets, the analysts say. Berenberg analysts are less optimistic about Roche's key clinical results this year, seen as high-risk as they started before the company launched initiatives aimed at improving R&D decision-making. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 02, 2025 02:25 ET (06:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。